Robert J. Casson

Robert J. Casson

MBBS (Hons), FRANZCO, DPhil, M.Biostatistics, GAICD

Ophthalmologist

33+ years of Experience

Male📍 Adelaide

About of Robert J. Casson

Robert J. Casson is an ophthalmologist based in North Terrace, Adelaide, SA 5000. He looks after a wide range of eye health needs, from everyday sight problems to more complex conditions that need ongoing care.

With 33+ years of experience, Robert has seen how eye conditions can change over time. In many cases, he helps people manage long-term issues like glaucoma and ocular hypertension, where keeping pressure under control can make a real difference. He also treats people with age-related macular degeneration and cataracts, including cataract removal when it’s the right next step.

Robert’s clinic work covers both front-of-eye problems and deeper eye issues. That can include diabetic eye problems such as diabetic retinopathy and diabetic macular oedema, as well as retinal problems like retinal detachment and late-onset retinal degeneration. He also treats inflammatory eye conditions such as uveitis and at times other less common causes of vision change.

Treatment can include surgical and medical care, depending on the situation. For example, he performs procedures such as trabeculectomy for glaucoma and vitrectomy for certain retinal problems. He works with the bigger picture too, because eye disease often links with other health factors like blood sugar and blood pressure.

Robert’s training includes an MBBS (Hons) from the University of Adelaide. He is a Fellow of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO). He also completed a DPhil at the University of Oxford (Nuffield Laboratory of Ophthalmology) and later added a Master of Biostatistics through the University of Adelaide. This mix of clinical and research training helps him use evidence and careful data when planning care. He also holds GAICD through the Australian Institute of Company Directors.

Over the years, his work has included research and publication, alongside day-to-day clinical care. If someone is unsure where their symptoms fit, Robert takes a clear, calm approach. He focuses on understanding the cause, explaining options in plain language, and helping patients make decisions they feel comfortable with.

Education

  • MBBS (Hons); University of Adelaide, Australia; 1992
  • FRANZCO (Fellow of the Royal Australian and New Zealand College of Ophthalmologists); Royal Australian and New Zealand College of Ophthalmologists; 2000
  • DPhil (Doctor of Philosophy); University of Oxford, Nuffield Laboratory of Ophthalmology; 2004
  • M.Biostatistics (Master of Biostatistics); University of Adelaide, Australia; 2012
  • GAICD (Graduate, Australian Institute of Company Directors); Australian Institute of Company Directors

Services & Conditions Treated

GlaucomaOcular Hypertension (OHT)Pigment-Dispersion SyndromeGanglion CystLate-Onset Retinal DegenerationTrabeculectomyAge-Related Macular Degeneration (ARMD)CataractCataract RemovalCerebral HypoxiaCone DystrophyRetinitis PigmentosaRetinopathy Pigmentary Mental RetardationVitrectomyAniridiaCongenital CataractConjunctivitis (Pink Eye)Diabetic Macular Edema (DME)Diabetic RetinopathyHypertensionIridectomyMicrophthalmiaMucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome)NearsightednessPresbyopiaRetinal DetachmentTrachomaUveitisWallerian Degeneration

Publications

5 total
Topical Dorzolamide for Macular Holes: A Randomised, Double-Blind, Placebo-Controlled Trial-Response.

Clinical & experimental ophthalmology • February 15, 2025

Yong Lee, Bobak Bahrami, Robert Casson, Weng Chan

We thank Abihaidar et al. for their insightful comments [1] on our study [2], which are discussed below. Abihaider et al. suggested a primary endpoint of 12-16 weeks. There is evidence to support surgical intervention for full-thickness macular holes (FTMH) within 3 months to optimise anatomical and visual acuity outcomes. Most spontaneous clo-sures are observed within 3 months, while the risk of FTMH progression increases around this time [3]. While more recent evidence suggests FTMH closure may occur up to 13 weeks with carbonic anhydrase inhibitors (CAIs), this data was unavailable during our study period [4]. As all patients were consented for surgery by the third month, extending the study period may have risked adverse outcomes for the participants. The patient (Number 10) referred to by Abihaider et al. [1] continued to re-port subjective metamorphopsia and central blurring vision de spite closure of the hole, which warranted proceeding to surgical intervention by week 12 as per the study protocol. We agree that future RCTs could consider extending the study period to 12 or 16 weeks to investigate the efficacy of CAIs. Additional data regarding the staging of posterior vitreous detachment (PVD) and epiretinal membrane location and epi-centres were important aspects raised by Abihaider et al. [1].Closure with topical therapy was observed in 2 of the 11 stage4 PVD cases (1 dorzolamide group. 1 placebo group), 3 of the 12 stage 3 PVD cases (2 dorzolamide group, 1 placebo group)and 1 of the 9 stage 2 PVD cases (placebo group) (see Table 1).The staging of PVD in our data did not seem to correlate withhigher or lower rates of closure with topical dorzolamidetherapy [2]. Vitreomacular traction (VMT) was present in seven cases, none of which underwent hole closure with topical therapy (three dor zolamide group, four placebo group). Our data supported that FTMH with an additional tractional component in its pathology (as in VMT) is less likely to close spontaneously or with topical dorzolamide therapy (zero of seven cases) [2]. Only three eyes in each group had epiretinal membrane, which were all macular in location. The numbers were too small to comment on the effect of ERM epicentre on this. Furthermore, there is no agreed grading of ERM in the setting of a FTMH, so this was not further elaborated. Duration of FTMH symptoms was only available for 15 of 32 cases (average of 8.44 weeks) [2]. Thus, it was difficult to include this for analysis too. Future clinical trials with larger numbers may provide more analyses on the impact of these factors. We investigated the efficacy of topical dorzolamide on stage 2 FTMH as per Gass classification system, defined as FTMH less than 400 µm. Our reasoning for this patient selection was to further evaluate the findings of Su et al.; a case series of 4 FTMH <300µm that underwent closure with topical dorzol-amide therapy [5]. We agree that investigation of small holes, as defined in the International Vitreomacular Traction Study, would be a worthwhile endeavour.

Identification of Genetic Variants Causing Paediatric Cataract in Myanmar.

Clinical Genetics • January 27, 2025

Johanna Jones, Daisy Boardman, Khine Nweni, Franoli Edo, Isabelly Barros De Lima, Pakdhipat Lertsinpakdee, Soe Hlaing, Robert Casson, Ashwin Mallipatna, Ye Win, Bennet Mccomish, Naing Lin, James Muecke, Andy Griffiths, Martin Holmes, Than Aung, Kathryn Burdon

Genetic testing for paediatric cataract detects a cause in 50%-70% of affected children but is as low as 20% in some reports. We screened 180 cataract-related genes in 22 children (from 20 families) with paediatric cataract from Myanmar using whole-exome sequencing. Pathogenic or likely pathogenic variants were identified in 45% (9/20) of probands in genes MIP, COL2A1, NHS, GJA8, GJA3, CRYGC, CRYBB2, PAX6 and SLC7A8. Variants of uncertain significance likely to be important were identified in three children for a maximum diagnostic rate of 12/20 probands (60%) comparable to other reports. This is the first study to examine the genetics of paediatric cataract in Myanmar.

Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases.

Progress In Retinal And Eye Research • January 20, 2025

A Geiger, J Kennedy, L Staker, T Wensel, R Casson, P Thomas

Inherited retinal diseases (IRDs), such as retinitis pigmentosa, are a heterogenous group of genetic eye diseases characterized by degeneration of photoreceptors. They are the leading cause of blindness in the working age population in high-income countries and are an ideal target for the expanding gene editing tool kit, including rapidly evolving CRISPR/Cas9 technology. In this review, we provide a comprehensive analysis of CRISPR/Cas9 technologies currently being explored as therapeutic interventions for IRDs. Given the challenges posed by the growing complexity and size of gene editing systems, the delivery of these therapeutics to the retina has necessitated innovative approaches. We review current delivery methods, including nanoparticles, virus-like particles and traditional viral vectors, highlighting their advantages and limitations. This review underscores the potential transformative impact of gene editing on genetic disease management, emphasising that advancements in these technologies, coupled with improved pre-clinical models, bring clinically safe and effective treatments for IRDs within view.

Evaluation of Glyoxal fixation for immunohistochemistry of the retina.

Scientific Reports • January 19, 2025

Glyn Chidlow, John P Wood, Weng Chan, Robert Casson

Immunohistochemistry has become an essential tool in retinal research. Formaldehyde is the gold standard fixative, but the development of an improved fixative is of keen interest. Herein, we performed a comprehensive evaluation of the compatibility of glyoxal fixation with retinal immunohistochemistry, using wholemounts, cryosections and paraffin-embedded eyes. Immunohistochemistry was performed in normal rat eyes, and, to facilitate localisation of stress-response proteins, eyes subjected to laser-induced retinal injury or injected with the endotoxin lipopolysaccharide. Regarding wholemounts, glyoxal fixation produced retinas that were too fragile to be consistently dissected as pristine wholemounts. In terms of antigenicity, we observed no consistent improvement when glyoxal fixation was used. Some antibodies produced higher signal intensities, but a greater number displayed weaker signal-to-background patterns of labelling compared to formaldehyde fixation. For cryosections and paraffin sections, we likewise found no compelling evidence that immunohistochemical signals were intensified when formaldehyde was replaced by glyoxal. For the 50 antibodies tested, formaldehyde typically produced signal-to-background immunolabelling that was equivalent or superior to glyoxal. In conclusion, the results of this study do not support the use of glyoxal fixation for immunohistochemistry of the rat retina, but with the caveat that improved formulations and protocols may address the limitations exposed herein.

Evaluating the weighting of extracurricular involvement in standardised curriculum vitae scoring criteria for entrance into Australian medical and surgical speciality training programs.

Australian Health Review : A Publication Of The Australian Hospital Association • December 26, 2024

Matthew Robertson, Thomas Muecke, Stephen Bacchi, Robert Casson, Weng Chan

ObjectiveThis study aims to evaluate how extracurricular involvement, such as sports, music, volunteering and teaching, are weighted within standardised curriculum vitae (CV) scoring criteria for medical officers applying to medical and surgical specialty training programs in Australia.MethodsA cross-sectional observational analysis of point allocations for extracurricular involvement was performed, as detailed by publicly available standardised CV scoring criteria for medical and surgical training programs. The analysis includes all specialty training programs in Australian and New Zealand listed by the Australian Health Practitioner Regulation Agency that publish these criteria for the 2023 intake.ResultsOf the 47 reviewed specialty training programs, 14 publish publicly available standardised CV scoring criteria, and 8 of these allocate points for extracurricular involvement. The mean weighting for extracurricular involvement was 11.5% (range 4.5-20%), compared with 42.5% for research. The allocation of points varies by training program and subdomain.ConclusionThe weighting of extracurricular involvement within standardised CV scoring criteria is limited and varied among specialty training programs, despite alignment with non-cognitive competencies emphasised by training frameworks. Current emphasis on academic achievements may disadvantage applicants with limited access to research opportunities. Greater clarity and consistency in evaluating non-academic attributes may support fairer, more holistic selection processes.

Frequently Asked Questions

What services does Dr Robert J. Casson offer?
Dr Casson provides glaucoma care, ocular hypertension, cataracts and cataract removal, vitrectomy, retinal conditions like age-related macular degeneration and diabetic eye disease, and various eye surgeries such as trabeculectomy and iridectomy.
Which eye conditions does he commonly treat?
He treats glaucoma, ocular hypertension, diabetic macular edema, diabetic retinopathy, age-related macular degeneration, retinal detachment, cone dystrophy, retinitis pigmentosa, and uveitis, among others.
Where is the clinic located?
The practice is on North Terrace in Adelaide, SA 5000, Australia.
What qualifications does Dr Casson hold?
He holds MBBS (Hons), FRANZCO, DPhil, M.Biostatistics, and GAICD, along with FRANZCO membership from the Royal Australian and New Zealand College of Ophthalmologists.
How many years of experience does he have?
He has more than 33 years of experience in ophthalmology.
How do I arrange an appointment with him?
Please contact the practice to book an appointment. They can arrange consultations for glaucoma, cataract evaluation, retinal conditions, and other eye concerns.

Contact Information

North Terrace, Adelaide, SA 5000, Australia

Is this your profile?

Claim this profile →

Memberships

  • Royal Australian and New Zealand College of Ophthalmologists (RANZCO)
  • Academy of Asia-Pacific Professors of Ophthalmology (AAPPO)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Australian and New Zealand Glaucoma Society (ANZGS)
  • European Society of Cataract and Refractive Surgeons (ESCRS)